“Evaluation of Paclitaxel As a Non-Cross-Resistant Agent in Cisplatin-Resistant Small Cell Lung Cancer (SCLC)”. 2025. International Cancer Research Journal 1 (1): 2. https://doi.org/10.70844/icrj.2025.1.2.